Table 2.
Antihyperglycemic medication at baseline in the overall population and by GLP-1RA status
| N (%) | Total | GLP-1RA-naïve | GLP-1RA switchers |
| N | 1212 | 960 | 252 |
| Metformin | 941 (77.6) | 755 (78.6) | 186 (73.8) |
| Sulfonylureas | 228 (18.8) | 173 (18.0) | 55 (21.8) |
| Alpha-glucosidase inhibitors | 5 (0.4) | 1 (0.1) | 4 (1.6) |
| Thiazolidinediones | 39 (3.2) | 26 (2.7) | 13 (5.2) |
| DPP-4 inhibitors | 201 (16.6) | 193 (20.1) | 8 (3.2) |
| SGLT-2 inhibitors | 499 (41.2) | 377 (39.3) | 122 (48.4) |
| Other antihyperglycemic drugs excluding insulin | 16 (1.3) | 12 (1.3) | 4 (1.6) |
| Basal insulin | 421 (34.7) | 303 (31.6) | 118 (46.8) |
| Premixed insulin | 55 (4.5) | 41 (4.3) | 14 (5.6) |
| Fast-acting insulin | 170 (14.0) | 132 (13.8) | 38 (15.1) |
| No medication | 26 (2.1) | 26 (2.7) | 0 |
| Oral antihyperglycemic drug only | 576 (47.5) | 576 (60.0) | 0 |
Data are from the full analysis set. Details on use of antihyperglycemic medication among other patient subgroups are included in the supplementary material.
DPP-4, dipeptidyl peptidase-4; GLP-1RA, glucagon-like peptide-1 receptor agonist; SGLT-2, sodium–glucose cotransporter-2.